Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer

David C. Binder, Boris Engels, Ainhoa Arina, Ping Yu, James M. Slauch, Yang Xin Fu, Theodore Karrison, Byron Burnette, Christian Idel, Ming Zhao, Robert M. Hoffman, David H. Munn, Donald A. Rowley, Hans Schreiber

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Immunogenic tumors grow progressively even when heavily infiltrated by CD8(+) T cells. We investigated how to rescue CD8(+) T cell function in long-established immunogenic melanomas that contained a high percentage of endogenous PD-1(+) tumor-specific CD8(+) T cells that were dysfunctional. Treatment with αPD-L1 and αCTLA-4 blocking antibodies did not prevent tumors from progressing rapidly. We then tested exogenous tumor-specific antigen delivery into tumors using Salmonella Typhimurium A1-R to increase antigen levels and generate a proinflammatory tumor microenvironment. Antigen-producing A1-R rescued the endogenous tumor-specific CD8(+) T cell response: proliferation was induced in the lymphoid organs and effector function was recovered in the tumor. Treatment with antigen-producing A1-R led to improved mouse survival and resulted in 32% rejection of long-established immunogenic melanomas. Following treatment with antigen-producing A1-R, the majority of tumor-specific CD8(+) T cells still expressed a high level of PD-1 in the tumor. Combining antigen-producing A1-R with αPD-L1 blocking antibody enhanced the expansion of tumor-specific CD8(+) T cells and resulted in 80% tumor rejection. Collectively, these data demonstrate a powerful new therapeutic approach to rescue dysfunctional endogenous tumor-specific CD8(+) T cells and eradicate advanced immunogenic tumors.

Original languageEnglish (US)
Pages (from-to)123-133
Number of pages11
JournalCancer immunology research
Volume1
Issue number2
DOIs
StatePublished - Aug 1 2013

Fingerprint

Bacterial Vaccines
T-Lymphocytes
Antigens
Neoplasms
Blocking Antibodies
Melanoma
Tumor Microenvironment
Neoplasm Antigens
Salmonella typhimurium

Keywords

  • CD8+ T cell rescue
  • PD-L1
  • S. Typhimurium
  • Tumor rejection
  • vaccine

ASJC Scopus subject areas

  • Immunology
  • Cancer Research

Cite this

Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. / Binder, David C.; Engels, Boris; Arina, Ainhoa; Yu, Ping; Slauch, James M.; Fu, Yang Xin; Karrison, Theodore; Burnette, Byron; Idel, Christian; Zhao, Ming; Hoffman, Robert M.; Munn, David H.; Rowley, Donald A.; Schreiber, Hans.

In: Cancer immunology research, Vol. 1, No. 2, 01.08.2013, p. 123-133.

Research output: Contribution to journalArticle

Binder, DC, Engels, B, Arina, A, Yu, P, Slauch, JM, Fu, YX, Karrison, T, Burnette, B, Idel, C, Zhao, M, Hoffman, RM, Munn, DH, Rowley, DA & Schreiber, H 2013, 'Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer', Cancer immunology research, vol. 1, no. 2, pp. 123-133. https://doi.org/10.1158/2326-6066.CIR-13-0058
Binder, David C. ; Engels, Boris ; Arina, Ainhoa ; Yu, Ping ; Slauch, James M. ; Fu, Yang Xin ; Karrison, Theodore ; Burnette, Byron ; Idel, Christian ; Zhao, Ming ; Hoffman, Robert M. ; Munn, David H. ; Rowley, Donald A. ; Schreiber, Hans. / Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. In: Cancer immunology research. 2013 ; Vol. 1, No. 2. pp. 123-133.
@article{dac75c60110b4742bc3244683c328e65,
title = "Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer",
abstract = "Immunogenic tumors grow progressively even when heavily infiltrated by CD8(+) T cells. We investigated how to rescue CD8(+) T cell function in long-established immunogenic melanomas that contained a high percentage of endogenous PD-1(+) tumor-specific CD8(+) T cells that were dysfunctional. Treatment with αPD-L1 and αCTLA-4 blocking antibodies did not prevent tumors from progressing rapidly. We then tested exogenous tumor-specific antigen delivery into tumors using Salmonella Typhimurium A1-R to increase antigen levels and generate a proinflammatory tumor microenvironment. Antigen-producing A1-R rescued the endogenous tumor-specific CD8(+) T cell response: proliferation was induced in the lymphoid organs and effector function was recovered in the tumor. Treatment with antigen-producing A1-R led to improved mouse survival and resulted in 32{\%} rejection of long-established immunogenic melanomas. Following treatment with antigen-producing A1-R, the majority of tumor-specific CD8(+) T cells still expressed a high level of PD-1 in the tumor. Combining antigen-producing A1-R with αPD-L1 blocking antibody enhanced the expansion of tumor-specific CD8(+) T cells and resulted in 80{\%} tumor rejection. Collectively, these data demonstrate a powerful new therapeutic approach to rescue dysfunctional endogenous tumor-specific CD8(+) T cells and eradicate advanced immunogenic tumors.",
keywords = "CD8+ T cell rescue, PD-L1, S. Typhimurium, Tumor rejection, vaccine",
author = "Binder, {David C.} and Boris Engels and Ainhoa Arina and Ping Yu and Slauch, {James M.} and Fu, {Yang Xin} and Theodore Karrison and Byron Burnette and Christian Idel and Ming Zhao and Hoffman, {Robert M.} and Munn, {David H.} and Rowley, {Donald A.} and Hans Schreiber",
year = "2013",
month = "8",
day = "1",
doi = "10.1158/2326-6066.CIR-13-0058",
language = "English (US)",
volume = "1",
pages = "123--133",
journal = "Cancer immunology research",
issn = "2326-6066",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer

AU - Binder, David C.

AU - Engels, Boris

AU - Arina, Ainhoa

AU - Yu, Ping

AU - Slauch, James M.

AU - Fu, Yang Xin

AU - Karrison, Theodore

AU - Burnette, Byron

AU - Idel, Christian

AU - Zhao, Ming

AU - Hoffman, Robert M.

AU - Munn, David H.

AU - Rowley, Donald A.

AU - Schreiber, Hans

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Immunogenic tumors grow progressively even when heavily infiltrated by CD8(+) T cells. We investigated how to rescue CD8(+) T cell function in long-established immunogenic melanomas that contained a high percentage of endogenous PD-1(+) tumor-specific CD8(+) T cells that were dysfunctional. Treatment with αPD-L1 and αCTLA-4 blocking antibodies did not prevent tumors from progressing rapidly. We then tested exogenous tumor-specific antigen delivery into tumors using Salmonella Typhimurium A1-R to increase antigen levels and generate a proinflammatory tumor microenvironment. Antigen-producing A1-R rescued the endogenous tumor-specific CD8(+) T cell response: proliferation was induced in the lymphoid organs and effector function was recovered in the tumor. Treatment with antigen-producing A1-R led to improved mouse survival and resulted in 32% rejection of long-established immunogenic melanomas. Following treatment with antigen-producing A1-R, the majority of tumor-specific CD8(+) T cells still expressed a high level of PD-1 in the tumor. Combining antigen-producing A1-R with αPD-L1 blocking antibody enhanced the expansion of tumor-specific CD8(+) T cells and resulted in 80% tumor rejection. Collectively, these data demonstrate a powerful new therapeutic approach to rescue dysfunctional endogenous tumor-specific CD8(+) T cells and eradicate advanced immunogenic tumors.

AB - Immunogenic tumors grow progressively even when heavily infiltrated by CD8(+) T cells. We investigated how to rescue CD8(+) T cell function in long-established immunogenic melanomas that contained a high percentage of endogenous PD-1(+) tumor-specific CD8(+) T cells that were dysfunctional. Treatment with αPD-L1 and αCTLA-4 blocking antibodies did not prevent tumors from progressing rapidly. We then tested exogenous tumor-specific antigen delivery into tumors using Salmonella Typhimurium A1-R to increase antigen levels and generate a proinflammatory tumor microenvironment. Antigen-producing A1-R rescued the endogenous tumor-specific CD8(+) T cell response: proliferation was induced in the lymphoid organs and effector function was recovered in the tumor. Treatment with antigen-producing A1-R led to improved mouse survival and resulted in 32% rejection of long-established immunogenic melanomas. Following treatment with antigen-producing A1-R, the majority of tumor-specific CD8(+) T cells still expressed a high level of PD-1 in the tumor. Combining antigen-producing A1-R with αPD-L1 blocking antibody enhanced the expansion of tumor-specific CD8(+) T cells and resulted in 80% tumor rejection. Collectively, these data demonstrate a powerful new therapeutic approach to rescue dysfunctional endogenous tumor-specific CD8(+) T cells and eradicate advanced immunogenic tumors.

KW - CD8+ T cell rescue

KW - PD-L1

KW - S. Typhimurium

KW - Tumor rejection

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=84892907751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892907751&partnerID=8YFLogxK

U2 - 10.1158/2326-6066.CIR-13-0058

DO - 10.1158/2326-6066.CIR-13-0058

M3 - Article

VL - 1

SP - 123

EP - 133

JO - Cancer immunology research

JF - Cancer immunology research

SN - 2326-6066

IS - 2

ER -